Bruker Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bruker in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Bruker stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BRKR, but not buy additional shares or sell existing shares.
View analyst ratings for Bruker or view top-rated stocks.

Wall Street analysts have given Bruker a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bruker wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Bruker saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,550,000 shares, an increase of 22.0% from the May 31st total of 1,270,000 shares. Based on an average daily trading volume, of 625,800 shares, the short-interest ratio is currently 2.5 days. Currently, 1.5% of the shares of the stock are sold short.
View Bruker's Short Interest.

Bruker is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Bruker.

Bruker will be holding an earnings conference call on Monday, August 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10158977".

Bruker Co. (NASDAQ:BRKR) released its quarterly earnings data on Tuesday, May, 4th. The medical research company reported $0.44 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.32 by $0.12. The medical research company earned $554.70 million during the quarter, compared to analysts' expectations of $506.56 million. Bruker had a trailing twelve-month return on equity of 26.44% and a net margin of 9.63%. The company's revenue for the quarter was up 30.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share.
View Bruker's earnings history.

Bruker's stock was trading at $40.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BRKR shares have increased by 105.6% and is now trading at $82.25.
View which stocks have been most impacted by COVID-19.

Bruker announced a quarterly dividend on Thursday, May 13th. Stockholders of record on Tuesday, June 1st will be paid a dividend of $0.04 per share on Friday, June 18th. This represents a $0.16 dividend on an annualized basis and a yield of 0.19%. The ex-dividend date is Friday, May 28th.
View Bruker's dividend history.

Bruker pays an annual dividend of $0.16 per share and currently has a dividend yield of 0.19%. Bruker does not yet have a strong track record of dividend growth. The dividend payout ratio of Bruker is 11.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bruker will have a dividend payout ratio of 7.41% next year. This indicates that Bruker will be able to sustain or increase its dividend.
View Bruker's dividend history.

Bruker issued an update on its FY 2021 earnings guidance on Thursday, July, 15th. The company provided earnings per share (EPS) guidance of $1.840-$1.890 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.870. The company issued revenue guidance of $2.31 billion-$2.35 billion, compared to the consensus revenue estimate of $2.32 billion.

7 equities research analysts have issued twelve-month price targets for Bruker's stock. Their forecasts range from $50.00 to $85.00. On average, they expect Bruker's stock price to reach $66.50 in the next year. This suggests that the stock has a possible downside of 19.1%.
View analysts' price targets for Bruker or view top-rated stocks among Wall Street analysts.

75 employees have rated Bruker CEO Frank H. Laukien on Glassdoor.com. Frank H. Laukien has an approval rating of 54% among Bruker's employees. This puts Frank H. Laukien in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Bruker include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Charles River Laboratories International (CRL), PerkinElmer (PKI), Bio-Techne (TECH), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of BRKR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bruker investors own include AbbVie (ABBV), CVS Health (CVS), Micron Technology (MU), Cisco Systems (CSCO), Intel (INTC), Alibaba Group (BABA), The Walt Disney (DIS), Applied Materials (AMAT), Bank of America (BAC) and Bristol-Myers Squibb (BMY).

Bruker trades on the NASDAQ under the ticker symbol "BRKR."

Bruker's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (1.96%), Boston Trust Walden Corp (0.10%), Rice Hall James & Associates LLC (0.03%), GWM Advisors LLC (0.02%), Dupont Capital Management Corp (0.01%) and Fisher Asset Management LLC (0.01%). Company insiders that own Bruker stock include Burkhard Prause, Cynthia M Friend, Marc A Kastner and Mark Munch.
View institutional ownership trends for Bruker.

BRKR stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Boston Trust Walden Corp, Rice Hall James & Associates LLC, HighPoint Advisor Group LLC, Zurcher Kantonalbank Zurich Cantonalbank , and Convergence Investment Partners LLC. Company insiders that have sold Bruker company stock in the last year include Cynthia M Friend, and Marc A Kastner.
View insider buying and selling activity for Bruker or view top insider-selling stocks.

BRKR stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Dupont Capital Management Corp, USA Financial Portformulas Corp, Arkadios Wealth Advisors, GWM Advisors LLC, IFP Advisors Inc, Veriti Management LLC, and Fisher Asset Management LLC.
View insider buying and selling activity for Bruker or or view top insider-buying stocks.

Shares of BRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BRKR stock can currently be purchased for approximately $82.25.

Bruker has a market capitalization of $12.46 billion and generates $1.99 billion in revenue each year. The medical research company earns $157.80 million in net income (profit) each year or $1.35 on an earnings per share basis.

Bruker employs 7,400 workers across the globe.

The following companies are subsidiares of Bruker: Accel Instruments, Advances Diagnostic Solutions Pty. Ltd., Agapetus GmbH, Alicona Corporation, Alicona GmbH, Alicona Imaging, Alicona Imaging GmbH, Alicona Korea Pcific Ltd., Alicona Manufacturing Inc., Alicona SARL, Alicona UK Limited, Alicona s.r.l., Anasys Instruments Corporation, Anasys Instruments GmbH, Arxspan, Biocentra AS., Bruker (Beijing) Scientific Technology Co. Ltd., Bruker (Malaysia) SDN BHD, Bruker AXS GmbH, Bruker AXS Handheld Inc., Bruker AXS LLC, Bruker AXS Ltd., Bruker Advanced Supercon GmbH, Bruker Austria GmbH, Bruker Belgium S.A./N.V., Bruker BioSciences Securities Corporation, Bruker BioSpin AG, Bruker BioSpin Corporation, Bruker BioSpin GmbH, Bruker BioSpin K.K., Bruker BioSpin MRI GmbH, Bruker Business Support Center sp. z o.o, Bruker Daltonics GmbH, Bruker Daltonics Ltd., Bruker Daltonics Pty. Ltd., Bruker Daltonics S.r.l., Bruker Daltonik GmbH, Bruker Detection Corporation, Bruker EAS GmbH, Bruker Energy & Supercon Technologies Inc. , Bruker Espanola S.A., Bruker Finance B.V., Bruker France S.AS., Bruker HTS GmbH, Bruker India Scientific PVT Ltd., Bruker Invest AG, Bruker Italia S.r.l., Bruker JV Israel Ltd., Bruker JV UK Ltd., Bruker Korea Co. Ltd., Bruker Ltd., Bruker Mexicana S.A. de C.V., Bruker MicroCT N.V., Bruker Nano GmbH, Bruker Nano Inc., Bruker Nederland B.V., Bruker Nordic AB, Bruker OST LLC, Bruker Optics GmbH, Bruker Optics Inc. , Bruker Optik GmbH, Bruker PTY Ltd., Bruker Physik GmbH, Bruker Polska Sp. Z o.o., Bruker Portugal Unipessoal LDA, Bruker Scientific Instruments Hong Kong Co. Ltd., Bruker Scientific Israel Ltd., Bruker Scientific LLC, Bruker Singapore Pte. Ltd., Bruker South Africa (Pty) Ltd., Bruker Taiwan Co. Ltd., Bruker Turkey Teknolojik Sistemler Ticaret Ltd. Sirketi, Bruker UK Ltd., Bruker do Brasil Ltda., Bruker s.r.o., Hain LifeScience E.A. Ltd., Hain LifeScience GmbH, Hain LifeScience Solutions (Pty) Ltd., Hain LifeScience Spain S.L., Hain LifeScience UK Ltd., Hain LifeSciences S.A. Pty Ltd., Hydrostatic Extrusions Ltd., Hysitron, InCoaTec GmbH, InVivo Biotech Services GmbH, InVivo Biotech Svs GmbH, JPK Instruments Limited, JPK Instruments USA. Inc., JPK In­stru­ments, JUWE Laborgeraete, Jordan Valley Semiconductors, Keymaster Technologies, Luxendo, Luxendo GmbH, MAC Science, Merlin Diagnostika GmbH, Mestrelab Research S.L., Michrom Bioresources, Oncovision - Innovative Medical Imaging, PMOD Technologies, Prairie Technologies, Princeton Gamma-Tech Instruments Inc, Quantron, RI Research Instruments GmbH, Roentec AG, S.I.S. Surface Imaging Systems, SAS Biocentric, SCiLS GmbH, SkyScan, Socabim, VACUUMSCHMELZE GmbH & Co. KG, Vutara LLC, XGLabs S.r.l., and Yingsheng Technology.

Bruker was founded in 1960.

The official website for Bruker is www.bruker.com.

Bruker is headquartered at 40 Manning Road, Billerica MA, 01821.

Bruker's mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company can be reached via phone at (978) 663-3660 or via email at [email protected]